WCG IPO Presentation Deck

. G The IRB Business Model - "Fee-based IRB Touchpoints" Provide Highly Reliable Revenue Stream IRB Responsibilities Factors Driving Our Growth Increased Trial Complexity Larger Clinical Trials Focus on Chronic and Degenerative Diseases Advancing Protocol Design Drug/Device/Diagnostic Combination Trials 21 Initial Protocol Review 0 Trial Close Out Annual Trial Review VEEN Changes in Investigators Investigator / Site Review wcg Revenue Generated from Each Touchpoint During the Clinical Trial Protocol Amendments Initial Patient Recruitment Review Initial Protocol Review Patient Communications MEEN Initial Investigator and Site Review DNL Initial Informed Consent Review wcg

View entire presentation